Last reviewed · How we verify
Phase 4 Study of Argatroban for Preventing Restenosis After Extracranial Vertebral Artery Stenting
Argatroban is a selective thrombin inhibitor, and previous study had suggested that argatroban use post percutaneous coronary intervention could potentially prevent reocclusion. But there has no study on large sample of argatroban treated restenosis vertebral artery stenting. This study will test the safety and efficacy of the argatroban on prevent Occlusion and Restenosis in patients with Extracranial vertebral Artery Stenting.
Details
| Lead sponsor | Xinfeng Liu |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 114 |
| Start date | 2010-04 |
| Completion | 2013-07 |
Conditions
- CVD
Interventions
- Argatroban
- non-argatroban treated group
Primary outcomes
- restenosis — at half a year
Stenosis detected by DSA(digital subtraction angiography),CTA(CT angiography)or MRA(MR angiography)was measured according to NASCET(North American Symptomatic Carotid Endarterectomy Trial)method.Concretely, NASCET stenosis is calculated from the ratio of the linear luminal diameter of the narrowest segment of the diseased portion of the artery to the diameter of the artery beyond any poststenotic dilatation: NASCET=(1-md/C)×100%
Countries
China